Your browser doesn't support javascript.
loading
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Aogi, Kenjiro; Saeki, Toshiaki; Nakamura, Seigo; Kashiwaba, Masahiro; Sato, Nobuaki; Masuda, Norikazu; Rai, Yoshiaki; Ohno, Shinji; Kuroi, Katsumasa; Nishimura, Reiki; Miyakoda, Keiko; Akiyama, Futoshi; Kurosumi, Masafumi; Ikeda, Tadashi.
Afiliación
  • Aogi K; Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umemoto-machi, Matsuyama, Ehime, 791-0280, Japan. kaogi@shikoku-cc.go.jp
Int J Clin Oncol ; 18(4): 598-606, 2013 Aug.
Article en En | MEDLINE | ID: mdl-22833344
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Middle aged Idioma: En Año: 2013 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Middle aged Idioma: En Año: 2013 Tipo del documento: Article